Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  The Lancet Oncology

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(17)30422-9PMID 28734759PMCID PMC6207072
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406).

  2020cited by this paper
• Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).

  2017cited by this paper
• Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.

  2017cited by this paper
• Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

  2016cited by this paper
• Programmed death-1 blockade in mismatch repair deficient colorectal cancer.

  2016cited by this paper
• Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

  2016cited by this paper
• Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

  2016cited by this paper
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

  2016cited by this paper
• PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers.

  2016cited by this paper
• Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies.

  2016cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

  2015cited by this paper
• The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

  2015cited by this paper
• Population Norms for the EQ-5D

  2014cited by this paper
• Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

  2014cited by this paper
• Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).

  2014cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012

  2013cited by this paper
• BRAF mutations in colorectal cancer: clinical relevance and role in targeted therapy.

  2012cited by this paper
• Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer

  2011cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• NCCN Clinical Practice Guidelines in Oncology: colon cancer.

  2009cited by this paper
• Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

  2009cited by this paper
• Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes

  2005cited by this paper
• Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer

  2001cited by this paper
• Interpreting the significance of changes in health-related quality-of-life scores.

  1998cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• EuroQol--a new facility for the measurement of health-related quality of life.

  1990cited by this paper
• EuroQol : a new facility for the measurement of health-related quality of life

  1990cited by this paper

• Colorectal Cancer in Young Adults in Panama: Clinical, Molecular, and Epidemiological Characterization in a National Cohort

  2026cites this paper
• Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan

  2026cites this paper
• Single-cell mapping of tumor-driven macrophage reprogramming via ETV4-MC1R underlies immunotherapy resistance in colorectal cancer

  2026cites this paper
• Risk and Management of Bowel Obstruction in Colorectal Cancer Patients Undergoing Immunotherapy: A Cross-Sectional Multicenter Study

  2026cites this paper
• Optimizing immunotherapy for gastrointestinal tract cancers: clinical progress and perspectives

  2026cites this paper
• Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment—Implications for Therapy

  2026cites this paper
• Prediction of immunotherapeutic responses by a classifier model based on inflammation-associated tumor microenvironment signatures in colorectal cancer

  2026cites this paper
• Predicting Immunotherapy Outcomes in Colorectal Cancer Using Machine Learning and Multi-Omic Biomarkers: Development of a Real-Time Predictive Web Application

  2026cites this paper
• Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).

  2026cites this paper
• Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy

  2026cites this paper
• Palmitic acid-triggered B7H3 palmitoylation promotes immune escape

  2026cites this paper
• Poliovirus receptor (PVR) expression as a predictor of relapse in colorectal cancer: bioinformatics and virtual screening.

  2026cites this paper
• NOTCH3 attenuates cytotoxicity via RBPJ-dependent PVR upregulation to influence immunotherapy outcomes in colorectal cancer

  2026cites this paper
• Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer.

  2026cites this paper
• Prognostic impact of clinical factors in MSI-H/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: results from a multicenter real-world study

  2026cites this paper
• Immune microenvironment and treatment response of dMMR gastric cancer: Heterogeneity and implications for immunotherapy

  2026cites this paper
• Comparison of regorafenib and immunotherapy in colorectal cancer survival: A multicenter cohort study.

  2026cites this paper
• Targeting JAK/STAT axis in solid tumors: resolving the therapeutic paradox through upstream suppression and downstream disruption

  2026cites this paper
• Efficacy, Safety, and Survival Outcomes of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient Colorectal Cancer: A Retrospective, Multicenter Study.

  2026cites this paper
• ProMMF_Kron: a multimodal deep learning model for immunotherapy response prediction in stomach adenocarcinoma.

  2026cites this paper
• Photodynamic Therapy Combined with Systemic Treatment Achieves Significant Remission in Microsatellite Instability-High Locally Advanced Colorectal Cancer: A Case Report and Literature Review.

  2026cites this paper
• Decoding the tumor microenvironment remodeling orchestrated by CLEC3B+ inflammatory cancer-associated fibroblasts in lung adenocarcinoma immunotherapy: elucidation from pan-cancer spatially single-cell transcriptomics landscape

  2026cites this paper
• Evolution or Revolution in Colorectal Cancer Treatment: Present and Future of New Therapeutic Options. A Narrative Review

  2026cites this paper
• Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy

  2026cites this paper
• Biomarkers of Immunotherapy Response in Surgical Oncology

  2026cites this paper
• Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer.

  2026cites this paper
• Immunotherapy for microsatellite-stable colorectal cancer: overcoming resistance and exploring novel therapeutic strategies

  2026influential citation
• From Crisis to Cure: A Case Report of Pathologic Complete Response in a Young Male with BRAF-Mutant dMMR Metastatic Colorectal Cancer after Immunotherapy

  2026cites this paper
• Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors.

  2026cites this paper
• HOXB2 is a prognostic biomarker and correlated with immune infiltration in colorectal cancer and glioma.

  2026cites this paper
• Bowel Stenosis Following Immunotherapy in dMMR Colorectal Cancer: A Case Series.

  2026cites this paper
• Emerging Immunotherapeutic Approaches in Colorectal Cancer: From Checkpoint Inhibitors to CAR-T Cell and Viral Vector Vaccines.

  2026cites this paper
• Simultaneous double primary malignant tumors of MSS/pMMR ascending colon cancer and MSI-H/dMMR duodenal cancer with nearly 2 years of recurrence-free survival after MDT-guided comprehensive treatment: a case report

  2025cites this paper
• Multi-tissue expression and splicing data prioritise anatomical subsite- and sex-specific colorectal cancer susceptibility genes

  2025cites this paper
• Colorectal Cancers and Microsatellite Instability

  2025cites this paper
• Gut microbiome and colorectal cancer: From pathogenesis to treatment.

  2025cites this paper
• Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial

  2025cites this paper
• Does paired genetic testing improve targeted therapy choices and screening recommendations for patients with upper gastrointestinal cancers and their families? A prospective cohort of 42 patients

  2025cites this paper
• Targeting Werner Helicase: A novel combination strategy for MSI colorectal cancer.

  2025cites this paper
• Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

  2025cites this paper
• The role of tumor-associated macrophages and PD-1/PD-L1 networking in colorectal cancer

  2025cites this paper
• KLRG1 expression induces functional exhaustion of NK cells in colorectal cancer patients

  2025cites this paper
• Evaluation of Treatment Protocols Based on the ESMO-Magnitude of Clinical Benefit Scale for Gastrointestinal System Cancers and Their Relationship with Reimbursement Policies in Turkey.

  2025cites this paper
• ICOS+ CD4+ T cells promote antitumor immunity through Akt/STAT1/T-bet axis in MSS/pMMR colorectal cancer.

  2025cites this paper
• Promising immunotherapeutic treatments for colon cancer

  2025cites this paper
• Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges

  2025cites this paper
• Deciphering the Immunomodulatory Function of GSN + Inflammatory Cancer‐Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan‐Cancer Single‐Cell Landscape and Spatial Transcriptomics Analysis

  2025cites this paper
• Pattern of Deficient Mismatch Repair (dMMR)/ High Microsatellite Instability (MSI-H) Testing in India: A Questionnaire-Based Study

  2025cites this paper
• Reassessing the Prognostic Value of Lymph Node Metastasis in Deficient Mismatch Repair Colorectal Cancer

  2025cites this paper
• A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours

  2025cites this paper
• Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors

  2025cites this paper
• Integrated analysis identifies P4HA2 as a key regulator of STAT1-mediated colorectal cancer progression and a potential biomarker for precision therapy

  2025cites this paper
• SOX17: a new therapeutic target for immune evasion of colorectal cancer

  2025cites this paper
• Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment

  2025cites this paper
• Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

  2025cites this paper
• Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors combined with chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis

  2025cites this paper
• Fusobacterium nucleatum downregulated MLH1 expression in colorectal cancer by activating autophagy-lysosome pathway

  2025cites this paper
• Advanced biomaterials and delivery modalities to alleviate cancer therapy-induced inflammation.

  2025cites this paper
• Current status and progress of diagnosis and treatment of postoperative recurrence of gastrointestinal peritoneal metastases

  2025cites this paper
• The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies

  2025cites this paper
• Immunogenomic characteristics and prognostic implications of terminally exhausted CD8+ T cells in colorectal cancers

  2025cites this paper
• Impact of body composition on pathological response to neoadjuvant immunotherapy in dMMR/MSI-H colorectal cancer

  2025cites this paper
• The Tumor-Associated Neutrophils-Related Signatures Predict Prognosis and Indicate Immune Landscape in Colorectal Carcinoma

  2025cites this paper
• Identification and impact of microbiota-derived metabolites in ascites of ovarian and gastrointestinal cancer

  2025cites this paper
• Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies

  2025cites this paper
• Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers

  2025cites this paper
• Pseudomonas aeruginosa enhances anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells

  2025cites this paper
• MMR deficiency is frequent in colorectal carcinomas with diffuse SLFN11 immunostaining: clinicopathologic and molecular study of 31 cases identified among 3,300 tumors

  2025cites this paper
• New depths: exploring the current landscape of colorectal cancer

  2025cites this paper
• Pembrolizumab versus bevacizumab plus modified FOLFOX6 in metastatic MSI-H/dMMR colorectal cancer: a multicenter retrospective study with CT evaluation

  2025cites this paper
• CLINICAL DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS.

  2025cites this paper
• Sekundäre maligne Neoplasien auf dem Boden eines Lynch-Syndroms mit koinzidenter Colitis ulcerosa

  2025cites this paper
• Identifying the Function of Kinesin Superfamily Proteins in Gastric Cancer: Implications for Signal Transduction, Clinical Significance, and Potential Therapeutic Approaches.

  2025cites this paper
• Macrocarpal I induces immunogenic cell death and synergizes with immune checkpoint inhibition by targeting tubulin and PARP1 in colorectal cancer

  2025cites this paper
• Invasion and metastasis in cancer: molecular insights and therapeutic targets

  2025cites this paper
• p53: A player in the tumor microenvironment

  2025cites this paper
• CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

  2025cites this paper
• Circulating IL6 is involved in the infiltration of M2 macrophages and CD8+ T cells

  2025cites this paper
• P-Pev: micelle-like complexes transformed from tumor extracellular vesicles by PEG-PE for personalized therapeutic tumor vaccine.

  2025cites this paper
• Prognostic markers and molecular pathways in primary colorectal cancer with a high potential of liver metastases: a systems biology approach

  2025cites this paper
• Predicting immunotherapy prognosis and targeted therapy sensitivity of colon cancer based on a CAF-related molecular signature

  2025cites this paper
• Beta-2-microglobulin positive tumor cells and CD8 positive lymphocytes are associated with outcome in post-neoadjuvant colorectal cancer resections.

  2025cites this paper
• Assessment of HER2/Neu Expression in Colorectal Carcinomas and Its Correlation With Tumor Stage and Histopathology

  2025cites this paper
• Escalated Segmental and Modified Radiation Lobectomy Dosing for Yttrium-90 Radioembolization of Liver-Dominant Metastatic Colorectal Cancer: 10-year Outcomes.

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy

  2025cites this paper
• Protein arginine methyltransferase 6 enhances immune checkpoint blockade efficacy via the STING pathway in MMR-proficient colorectal cancer

  2025cites this paper
• Combination of immune checkpoint blockade in metastatic colorectal cancers with microsatellite instability: A new standard of care?

  2025cites this paper
• Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer

  2025cites this paper
• Upregulation of RIG‐I is Critical for Responsiveness to IFN‐α Plus Anti‐PD‐1 in Colorectal Cancer

  2025cites this paper
• Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer – Insights from the KEYNOTE-651

  2025cites this paper
• Pembrolizumab in Patients of Chinese Descent with Microsatellite Instability-high/Mismatch Repair Deficient Advanced Solid Tumors: KEYNOTE-158 Final Analysis

  2025cites this paper
• Liver Transplantation for Non-hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors.

  2025cites this paper
• Higher levels of VEGF-A and TNFα in patients with immune checkpoint inhibitor-induced inflammatory arthritis

  2025cites this paper
• CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges

  2025cites this paper
• Artificial intelligence in colorectal cancer liver metastases: From classification to precision medicine.

  2025cites this paper
• Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis

  2025cites this paper
• Prognostic and predictive molecular biomarkers in colorectal cancer

  2025cites this paper
• Single-cell and spatial transcriptomic analysis reveals that an immune cell-related signature could predict clinical outcomes for microsatellite-stable colorectal cancer patients receiving immunotherapy

  2025cites this paper
• Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review

  2025cites this paper